Aes-103 5-hydroxymethyl-2-furfural: Phase I/IIa data

A double-blind, U.S. Phase I/IIa in 18 patients with stable sickle cell disease showed that single oral doses of 300, 1,000, 2,000, and 4,000 mg Aes-103 were well tolerated with no severe adverse even...